Stocks Health care MCRB
NASDAQ · Health careSeres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc. brought in $1.9M of revenue over the twelve months to June 30, 2026. It posted a net loss of $22.5M. Operating cash flow minus capital spending left $865K of free cash flow in fiscal 2025. At June 30, 2026 it held $15.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Seres Therapeutics, Inc. does
Seres Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MCRB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $789K | $5.7M | $0.64 | $865K |
| 2024 | $0 | $136K | $0.00 | -$149M |
| 2023 | $0 | -$113.7M | -$17.77 | -$125.3M |
| 2022 | $7.1M | -$250.2M | -$46.12 | -$238.6M |
| 2021 | $144.9M | -$65.6M | -$14.38 | -$2.9M |
| 2020 | $33.2M | -$89.1M | -$22.36 | -$94.2M |
Latest SEC filings
What Seres Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- August 4, 2026
- August 4, 2026
- July 9, 2026
- July 8, 2026
- July 8, 2026
- June 5, 2026
- June 1, 2026
Questions about MCRB
What does Seres Therapeutics, Inc. do?
Seres Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MCRB.
Is Seres Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $22.5M on revenue of $1.9M.
How much revenue does Seres Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Seres Therapeutics, Inc. reported revenue of $1.9M.
When did Seres Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 18, 2026.
Similar companies
Follow MCRB
Get an email when Seres Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MCRB: get an email when it filesWhere the numbers come from
Financial figures are the values Seres Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.